Lepra recurrent developed after termination of antileprotic therapy

Cover Page


Cite item

Full Text

Abstract

Lepra is an infectious disease, granulomatosis caused by Mycobacterium leprae. It is characterized with prolonged latent period (from 3-5 years to several decades), low transmission, generally lesions of skin and peripheral nervous system. The recurrent of disease is possible after the termination of antileprotic therapy. A case report presented demonstrating the lepra recurrent in female patient 4 years after termination of therapy; that was conducted during 17 years and led to the regression of clinical symptoms and to negative results of bacterioscopic examination of nasal brushings and scratch samples from sites of former eruptions. This case should call attention of dermatologists and other physicians to the problem of leprosy recurrent diagnosis in previously observed and deregistered patients.

About the authors

A. A. Kubanov

State Research Center of Dermatovenereology and Cosmetology, Ministry of Healthcare of the Russian Federation

Author for correspondence.
Email: noemail@neicon.ru
Russian Federation

A. E. Karamova

State Research Center of Dermatovenereology and Cosmetology, Ministry of Healthcare of the Russian Federation

Email: Karamova@cnikvi.ru
Russian Federation

V. G. Semenova

State Research Center of Dermatovenereology and Cosmetology, Ministry of Healthcare of the Russian Federation

Email: noemail@neicon.ru
Russian Federation

V. A. Smoliannikova

State Research Center of Dermatovenereology and Cosmetology, Ministry of Healthcare of the Russian Federation

Email: noemail@neicon.ru
Russian Federation

M. A. Nefedova

State Research Center of Dermatovenereology and Cosmetology, Ministry of Healthcare of the Russian Federation

Email: noemail@neicon.ru
Russian Federation

References

  1. Graham A., Furlong S., Margoles L.M., Owusu K., Franco-Paredes C. Clinical management of leprosy reactions. Infect Dis Clin Pract 2010; 18: 235-238.
  2. Pattyn S.R. Search for effective short-course regimen for the treatment of leprosy. Int J Lepr Other Mycobact Dis 1993; 61 (1): 76-81.
  3. Walker S.L., Lockwood D.N. Leprosy. Clin Dermatol 2007; 25: 165-172.
  4. Smith W.C., Aerts A. Role of contact tracing and prevention strategies in the interruption of leprosy transmission. Lepr Rev 2014; 85: 2-17.
  5. Дуйко В.В. Эпидемиология и организация борьбы с лепрой в России в современных условиях. Актуальные вопросы клинической и экспериментальной лепрологии. Издательский дом «Астраханский университет» 2011; 6-16
  6. Выявлен новый случай заболевания лепрой в запущенной стадии. Доступно по адресу: http://inlep.ru/news/detail.php?ELEMENT_ID=51
  7. WHO Expert Committee on Leprosy. 7th Report (WHO Technical Report Series, No.874). Geneva: World Health Organization, 1998.
  8. Britton W.J., Lockwood D.N. Leprosy. Lancet 2004; 363: 1209-19.
  9. Eichelmann K., Gonzalez Gonzalez S.E., Salas- Alanis J.C., Ocampo-Candiani J. Leprosy. An update: definition, pathogenesis, classification, diagnosis, and treatment. Actas Dermosifiliogr 2013; 104 (7): 554-63.
  10. Martinez A.N., Talhari C., Moraes M.O., Talhari S. PCR-based techniques for leprosy diagnosis: from the laboratory to the clinic. PLoS Negl Trop Dis 2014; 8 (4): e2655. doi: 10.1371/ journal.pntd.0002655.
  11. Дегтярев О.В., Иншина Е.А., Метревели Г.В., Янчевская Е.Ю. Рецидивы лепры. Астраханский медицинский журнал 2015; (3): 6-14
  12. Prabu R., Manickam P., Mahalingam V.N., Jayasree P., Selvaraj V., Mehendale S.M. Relapse and deformity among 2177 leprosy patients released from treatment with MDT between 2005 and 2010 in South India: A retrospective cohort study. Lepr Rev 2015 Dec; 86 (4): 345-55
  13. Ishida Y., Ozaki M., Picorini L., Guglielmelli E. A recurrent case of BT leprosy with widely spread skin lesions showing a histopathology of indeterminate group after 4.5-years irregular treatment, Bangladesh. Nihon Hansenbyo Gakkai Zasshi 1999; 68 (3): 195-9.
  14. Kim E.J., Cho K.H., Yoon H.S., Cho S., Park H.S. An unsuspected case of relapsed multibacillary leprosy. Ann Dermatol 2014; 26 (6): 758-9.
  15. Matsuoka M., Kashiwabara Y., Liangfen Z., Goto M., Kitajima S. A second case of multidrug-resistant Mycobacterium leprae isolated from a Japanese patient with relapsed lepromatous leprosy. Int J Lepr Other Mycobact Dis 2003; 71 (3): 240-3.
  16. da Silva Rocha A., Cunha Md, Diniz L.M. et al. Drug and multidrug resistance among Mycobacterium leprae isolates from Brazilian relapsed leprosy patients. J Clin Microbiol 2012; 50 (6): 1912-7.
  17. Kar H.K., Sharma P. New lesions after MDT in PB and MB leprosy: a report of 28 cases. Indian J Lepr 2008; 80 (3): 247-55.

Supplementary files

Supplementary Files
Action
1. JATS XML

Copyright (c) 2016 Kubanov A.A., Karamova A.E., Semenova V.G., Smoliannikova V.A., Nefedova M.A.

Creative Commons License
This work is licensed under a Creative Commons Attribution 4.0 International License.

СМИ зарегистрировано Федеральной службой по надзору в сфере связи, информационных технологий и массовых коммуникаций (Роскомнадзор).
Регистрационный номер и дата принятия решения о регистрации СМИ: серия ПИ № ФС 77 - 60448 от 30.12.2014.


This website uses cookies

You consent to our cookies if you continue to use our website.

About Cookies